DiaMedica Inc. Announces Results of Annual General and Special Meeting

DiaMedica Inc. (TSX VENTURE:DMA), a biotechnology company focused on diabetes,
is pleased to announce that at the Annual General and Special Meeting (the
"Meeting") of shareholders of DiaMedica held on December 16, 2013, Michael
Giuffre, Rick Pauls, Dawson Reimer, Richard Pilnik and Thomas Wellner were
re-elected as the board of directors of DiaMedica. 


In addition to the election of directors, the shareholders passed all
resolutions placed before the Meeting as outlined in the management information
circular dated November 6, 2013, including re-appointment of KPMG LLP, Chartered
Accountants, as auditors for the upcoming year and authorizing the board of
directors of DiaMedica at its discretion to amend the Articles of Incorporation
of DiaMedica to consolidate the outstanding common shares of DiaMedica at a
future date on the basis of one pre-consolidation common share for each two to
five post-consolidation common share as more particularly described in the
management information circular. 


About DiaMedica

DiaMedica Inc. (TSX VENTURE:DMA) is a biotechnology company developing
first-in-class treatments for the treatment of diabetes. DiaMedica's lead
compound, DM199, is a recombinant human protein for the treatment of both Type 1
and Type 2 diabetes and their complications. The Company is also developing the
first therapeutic GPCR agonist monoclonal antibody, DM204, for the treatment of
Type 2 diabetes and cardiovascular disease. DiaMedica's shares trade on the TSX
Venture Exchange (TSX VENTURE:DMA). For more information please visit
www.diamedica.com.


FORWARD-LOOKING STATEMENTS 

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of the contents of this News
Release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica
Rick Pauls
President and CEO
763-710-4455
[e-mail]


DiaMedica
One Carlson Parkway, Suite 124
Minneapolis, MN
www.diamedica.com